Table: q1_q4_2019_prescription_drugs_wac_increases , manufacturer_name like M*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000190	Mallinckrodt ARD LLC	12/31/2019	63004871001	ACTHAR GEL 5ML INJECTION,1 MDV	12/31/2019	972.00	39864.00	None	Single Source Drug	None	1	None	1	Mallinckrodt has voluntarily made a public pledge on responsible drug pricing and innovation which is our social contract to those we serve and which can be found at https://www.mallinckrodt.com/corporate-responsibility/pledge-on-drug-pricing--innovation/. Our commitment is to price our innovative products responsibly while providing broad patient access. In so doing, we continue to invest in innovation that brings value to patients, providers, and the U.S. healthcare system through research and development, quality manufacturing, as well as through patient education and disease awareness. The current price increase for Acthar is not necessitated by a change or improvement to the drug but by the larger principles set forth in our pledge.	None	08/14/2014	Questcor Pharmaceuticals, Inc.	5900000000	None	Acquisition Price field reflects the total price paid for all of Questcor inclusive of Acthar Gel.	31626.00	None	2013	28686.00	None	None
Rx0000052	Mallinckrodt Hospital Products Inc.	03/31/2019	43825010201	OFIRMEV INJECTION 1000MG/100ML (10mg/ml) (24 vials/case)	02/11/2019	79.49	1043.00	06/06/2021	Single Source Drug	None	1	None	1	Mallinckrodt has voluntarily made a public pledge on responsible drug pricing and innovation which is our social contract to those we serve and which can be found at https://www.mallinckrodt.com/corporate-responsibility/pledge-on-drug-pricing--innovation/. Our commitment is to price our innovative products responsibly while providing broad patient access. In so doing, we continue to invest in innovation that brings value to patients, providers, and the U.S. healthcare system through research and development, quality manufacturing, as well as through patient education and disease awareness. The current price increase for Ofirmev is not necessitated by a change or improvement to the drug but by the larger principles set forth in our pledge.	None	03/19/2014	Cadence Pharmaceuticals, Inc.	1400000000	None	None	14.75	None	2011	10.75	None	None
Rx0000072	Mayne Pharma Inc	12/31/2019	51862006901	ESTAZOLAM 1MG TABLETS 100	11/06/2019	303.52	473.58	None	Non-innovator Multiple Source Drug	5700	None	CHANGING MARKET DYNAMICS	None	NONE	None	08/03/2016	ALLERGAN	None	None	Estazolam was acquired as part of a portfolio of drugs from Allergan and Teva with at a total cost of $652 million.	80.85	80.85	1999	39.69	None	None
Rx0000072	Mayne Pharma Inc	12/31/2019	51862007001	ESTAZOLAM 2MG TABLETS 100	11/06/2019	284.15	473.58	None	Non-innovator Multiple Source Drug	25800	None	CHANGING MARKET DYNAMICS	None	NONE	None	08/03/2016	ALLERGAN	None	None	Estazolam was acquired as part of a portfolio of drugs from Allergan and Teva with at a total cost of $652 million.	90.08	90.08	1999	43.75	None	None
Rx0000072	Mayne Pharma Inc	03/31/2019	51862026301	METHYLPHENIDATE EXTENDED RELEASE 20MG CAPSULES 100	03/19/2019	404.93	858.87	None	Non-innovator Multiple Source Drug	36287	None	CHANGING MARKET DYNAMICS	None	NONE	None	08/03/2016	ALLERGAN	None	1	Methylphenidate LA was acquired as part of a portfolio of drugs from Allergan and Teva with at a total cost of $652 million.	453.94	453.94	2012	453.94	None	None
Rx0000072	Mayne Pharma Inc	03/31/2019	51862026401	METHYLPHENIDATE EXTENDED RELEASE 30MG CAPSULES 100	03/19/2019	414.16	878.43	None	Non-innovator Multiple Source Drug	25668	None	CHANGING MARKET DYNAMICS	None	NONE	None	08/03/2016	ALLERGAN	None	1	Methylphenidate LA was acquired as part of a portfolio of drugs from Allergan and Teva with at a total cost of $652 million.	464.27	464.27	2012	464.27	None	None
Rx0000072	Mayne Pharma Inc	03/31/2019	51862026501	METHYLPHENIDATE EXTENDED RELEASE 40MG CAPSULES 100	03/19/2019	425.66	902.83	None	Non-innovator Multiple Source Drug	18552	None	CHANGING MARKET DYNAMICS	None	NONE	None	08/03/2016	ALLERGAN	None	1	Methylphenidate LA was acquired as part of a portfolio of drugs from Allergan and Teva with at a total cost of $652 million.	477.17	477.17	2012	477.17	None	None
Rx0000382	Melinta Therapeutics, LLC	12/31/2019	70842016010	MINOCIN (Minocycline-Hydrochloride) is administered via intravenous form and packaged as 10 VIAL in 1 CARTON > 1 INJECTION in 1 VIAL (1mg dose)	10/01/2019	159.78	1935.11	05/12/2031	Single Source Drug	None	1	Melinta seeks to provide innovative therapies to people impacted by acute and life-threatening illnesses. We are committed to the responsible pricing of our products, and our pricing methodology includes consideration of several financial and nonfinancial factors. Initial pricing, as well as any change in pricing, aims to reflect the clinical value of the product to patients and the healthcare system, while at the same time ensuring patient access. Financial factors include both our current investments in MINOCIN (minocycline) for Injection, as well as consideration for potential future investments in research or other lifecycle related matters that may be necessary.	None	None - see cost increase factors statement.	None	01/05/2018	The Medicines Company	None	1	None	1544.13	1544.13	2015	1470.60	None	None
Rx0000051	MILLICENT U.S., INC.	06/30/2019	72495020105	FEMRING 0.05MG/DAY (ESTRADIOL ACETATE VAGINAL RING) for 3 months usage, package size 1	04/20/2019	41.70	485.37	12/19/2015	Single Source Drug	None	1	None	1	None	1	05/18/2018	Allergan	None	1	None	443.67	443.67	2003	76.50	None	None
Rx0000051	MILLICENT U.S., INC.	06/30/2019	72495020210	FEMRING 0.10MG/DAY (ESTRADIOL ACETATE VAGINAL RING) for 3 months usage, package size 1	04/20/2019	44.44	517.23	12/19/2015	Single Source Drug	None	1	None	1	None	1	05/18/2018	Allergan	None	1	None	472.79	472.79	2003	81.50	None	None
Rx0000044	Mylan Institutional Inc	09/30/2019	67457022005	Isosulfan Blue 1% 50mg/5mL Liq 6s SUV	07/16/2019	466.98	5773.55	12/15/2028	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Mylan Institutional Inc. owns and sells the product through Mylan Institutional LLC, and the product has been owned and sold by Mylan Institutional LLC for the past five years. Mylan Institutional Inc. and Mylan Institutional LLC are both indirectly wholly-owned subsidiaries of Mylan N.V. FDA publishes, in the Orange Book, patent information for drugs approved under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FFDCA) as a NDA. Mylan’s product was approved under section 505(j) of the FFDCA as an ANDA.
Rx0000044	Mylan Institutional Inc	09/30/2019	67457025905	Isosulfan Blue N+ 1% 50mg/5mL Liq 6s SUV	07/16/2019	466.98	5773.55	12/15/2028	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Mylan Institutional Inc. owns and sells the product through Mylan Institutional LLC, and the product has been owned and sold by Mylan Institutional LLC for the past five years. Mylan Institutional Inc. and Mylan Institutional LLC are both indirectly wholly-owned subsidiaries of Mylan N.V. FDA publishes, in the Orange Book, patent information for drugs approved under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FFDCA) as a NDA. Mylan’s product was approved under section 505(j) of the FFDCA as an ANDA. The product launched on 11/13/2015 and the 5-year WAC history report reflects this launch date. Medispan incorrectly lists a WAC with an effective date of 07/26/2010 that is for NDC 67457-0220-05. Medispan also incorrectly lists a WAC increase for 04/01/2015.
Rx0000044	Mylan Institutional Inc	09/30/2019	67457058605	Isosulfan Blue PRX 1% 50mg/5mL Liq 6s SUV	07/16/2019	466.98	5773.55	12/15/2028	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Mylan Institutional Inc. owns and sells the product through Mylan Institutional LLC, and the product has been owned and sold by Mylan Institutional LLC for the past five years. Mylan Institutional Inc. and Mylan Institutional LLC are both indirectly wholly-owned subsidiaries of Mylan N.V. FDA publishes, in the Orange Book, patent information for drugs approved under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FFDCA) as a NDA. Mylan’s product was approved under section 505(j) of the FFDCA as an ANDA. The product launched on 11/13/2015 and the 5-year WAC history report reflects this launch date. Medispan incorrectly lists a WAC with an effective date of 03/20/2015.
Rx0000046	Mylan Specialty LP	09/30/2019	49502060530	Perforomist 20mcg/2mL 30x1	07/16/2019	24.31	510.45	06/22/2021	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product has been owned and sold by Mylan Specialty L.P., an indirectly wholly-owned subsidiary of Mylan N.V. for the past five years.
Rx0000046	Mylan Specialty LP	09/30/2019	49502060561	Perforomist 20mcg/2mL 60x1	07/16/2019	48.61	1020.86	06/22/2021	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product has been owned and sold by Mylan Specialty L.P., an indirectly wholly-owned subsidiary of Mylan N.V. for the past five years.
Rx0000046	Mylan Specialty LP	09/30/2019	00037682210	Proctofoam HC 1% 10g	07/16/2019	7.12	149.59	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Mylan Specialty L.P. owns and sells the product through Meda Pharmaceuticals, Inc. (“Meda”), and the product has been owned and sold by Meda for the past five years. Mylan Specialty L.P. and Meda are both indirectly wholly-owned subsidiaries of Mylan N.V. On August 5, 2016, Mylan N.V. (“Mylan”) completed the settlement of its recommended public offer to the shareholders of Meda to tender all of their shares in Meda to Mylan. Product underwent NDC change on 10/8/14 from Expired NDC: 68220-0142-10 to updated NDC: 0037-6822-10. As both NDCs were active during the 5-year price history for this product, the 68220-0142-10 NDC had an increase on 9/26/14 that is reported under the updated NDC with the 10/8/14 NDC change effective date in the 5-year price history report attached.